Paraguay Medical Device Regulation 2026: Risk Classification Clase I-IV and NSO Compliance

1. Key takeaways

1. Paraguay classifies devices into four classes (Clase I-IV), with the classification rules set out in Annex I of Resolución N° 226/2024; the technical responsible person (Regente) declares the rule and the class in DINAVISAPy together with a technical justification (Article 4), so the classification is an argued position filed by a named professional, not a free-text choice in a form.
2. For Classes II, III and IV, the class declaration is accepted or rejected by DINAVISA; a rejection must state technical grounds, the application is closed, and the file must be resubmitted with the fees paid again, which makes the quality of the initial justification a direct financial variable in the project budget.
3. Class I is classified by means of a sworn declaration (final paragraph of Article 4, following Annex II) and is cleared through the NSO, so the declaration form itself is the legal instrument on which the market release of the product rests.
4. Article 7 provides that an erroneous class declaration or one inconsistent with the classification rules renders the NSO invalid, and DINAVISA will: first, declare the NSO invalid; second, order the registration holder to withdraw the product from the market; and third, in case of repetition, after an administrative proceeding, close the premises temporarily or permanently. Moreover, once an NSO has been issued, no change may be requested for the declared Class I status, so there is no corrective filing after issuance.

2. Legal basis

3. Expert insights

Insight 1: classification operates on a declaration plus review model, not on a file-and-pass model. Article 4 places the burden of technical justification on the applicant, while DINAVISA retains the power to accept or reject the declared class. This differs from the pattern in some markets where companies self-classify and the regulator supervises afterwards: in Paraguay the file is cut off at the admission stage, and the price of a rejection is resubmission with a second payment of fees, not a request for correction. The economics of a poorly argued classification are therefore worse than they first appear, because both time and money are consumed in full. Rejections also restart the review queue, so the calendar impact is longer than the resubmission itself suggests. A model budget that assumes first-pass success on every classification will understate cost for portfolios with genuinely borderline products.

Insight 2: the responsibility structure of Class I is the inverse of that for Classes II to IV. A Class I product clears on the strength of a sworn declaration, with DINAVISA not reviewing technical documentation item by item, so the weight of responsibility rests on the applicant; for Classes II to IV the certificate is the conclusion of a review, so the weight rests on the assessment stage. Class I therefore looks simple but is in fact the route with the heaviest responsibility, and the three consequences in Article 7 are the designed counterweight to that allocation of risk. Applicants should therefore invest in the declaration itself, since it is both the release document and the liability document.

Insight 3: the rule that the class cannot be changed after NSO issuance is irreversible. This is harsher than a fine: once a product holds an NSO on a Class I declaration and is later found to belong in Class II, no correction can be requested; the product must go through the registration route afresh, and in the meantime it stands in a non-compliant state on the market. Classification judgment must therefore be completed and defended before submission, because there is no corrective path of the form obtain the certificate first and adjust the class later. The only route forward after a misclassification is a fresh application under the correct class, with all the fees, timeline and market interruption that a fresh application implies.

4. Practical recommendations

1. Have the classification justification prepared by qualified personnel, mapped clause by clause against the rules in Annex I, avoiding documents that state a conclusion without walking through the reasoning that supports it, since a bare conclusion is exactly what rejection decisions cite as missing, and version-control the justification so the filed text can be reproduced exactly in an inspection.
2. For borderline products at the Class I / Class II boundary, complete an internal three-level review before submission, and where doubt persists, seek a preliminary classification assessment first, because the cost of a wrong route exceeds by far the cost of asking early.
3. Where a Classes II to IV application is rejected, complete the technical argumentation in line with the stated grounds and resubmit, and include the second round of official fees in the project budget from the outset so a rejection does not stall the program for lack of funds.
4. After obtaining a Class I NSO, establish an annual self-inspection that verifies the continued consistency between the actual use of the product and the declared class, documenting the outcome so the review itself can be evidenced if the authority asks, and re-examine the declared class whenever a model, indication or material change is introduced.

5. Verification checklist

• □ Classification rules of Annex I obtained and compared item by item
• □ Classification technical justification signed by the technical responsible person
• □ Second submission fees budgeted for Classes II to IV applications
• □ Confirmed that no remedial path exists to change the class after a Class I NSO is issued
• □ Annual self-inspection mechanism for class consistency established
• □ Borderline products identified and documented with their class rationale

Regulatory information verified as of October 29, 2026.

GRZAN provides medical device registration support in Paraguay for manufacturers, importers and authorized representatives. For inquiries, contact info@grzanglobal.com.